A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA MHLW-Funded Study Group Designing New Care Delivery Model for Alzheimer’s
June 14, 2024
-
BUSINESS Lilly Set to Raise Profile as Only Eczema Player with Oral and Injectable Options
June 13, 2024
-
REGULATORY Honebuto Draft Equivocal on Off-Year Price Cuts, but Focuses on FY2025 Revision
June 12, 2024
-
ACADEMIA Akira Endo, Who Pioneered Discovery of Statins, Dies at 90
June 12, 2024
-
REGULATORY MHLW to Issue Nitrosamine Risk Communication Guidance by June-End; Draft Now Ready
June 11, 2024
-
COMMENTARY Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
-
BUSINESS Susana Murteira Tapped as Amgen Japan President
June 11, 2024
-
REGULATORY Japan Eyes Withdrawal Rule for Conditional Approval, More Flexible Nods
June 10, 2024
-
REGULATORY LDP Policy Board Endorses Fiscal Consolidation HQ’s Proposal to Extend CEAs
June 10, 2024
-
COMMENTARY With Only 5 Months Until Nitrosamine Self-Inspection Deadline, Many Challenges Remain
June 7, 2024
-
BUSINESS Overseas Sales Ratio of 25 Japan Drug Makers Reaches 67% in FY2023: Tally
June 6, 2024
-
ORGANIZATION 135 Meds Still in Lag/Loss State in Japan, JPMA Task Force Revving Up Fight
June 5, 2024
-
ORGANIZATION JPMA Pushing Industry-Academia Consortia in Non-Competitive Drug Discovery Fields
June 5, 2024
-
REGULATORY Japan Health Ministry Panel Gives Blessing to Novartis’ PNH Drug Iptacopan and More
June 4, 2024
-
REGULATORY Make Single IRB Mandatory in Multi-Center Trials That Use Competitive Funds: Deregulation Panel
June 4, 2024
-
BUSINESS Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
June 3, 2024
-
REGULATORY Nitrosamine Guideline to Be Proposed as New Topic for ICH at Fukuoka Confab
May 31, 2024
-
BUSINESS Moderna Submits RSV Vaccine in Japan
May 31, 2024
-
REGULATORY Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
May 30, 2024
-
BUSINESS Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…